• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[间变性淋巴瘤激酶在非小细胞肺癌中的现状]

[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].

作者信息

Song Peng, Zhang Li, Shang Congcong

机构信息

Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):703-711. doi: 10.3779/j.issn.1009-3419.2018.09.10.

DOI:10.3779/j.issn.1009-3419.2018.09.10
PMID:30201071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6136995/
Abstract

The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.

摘要

间变性淋巴瘤激酶（ALK）基因重排在非小细胞肺癌（NSCLC）中的发生率约为3%至5%。近年来，ALK基因抑制剂取得了重大突破，显著延长了ALK（+）晚期NSCLC患者的生存期。但大多数患者在治疗后会出现获得性耐药。本文从ALK基因背景、检测方法、三代ALK抑制剂的治疗以及耐药后的策略等方面进行了阐述，以期对临床工作有参考价值和借鉴意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/aa4fbd89ce82/zgfazz-21-9-703-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/2ae58857a84f/zgfazz-21-9-703-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/bbf67fd3e699/zgfazz-21-9-703-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/aa4fbd89ce82/zgfazz-21-9-703-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/2ae58857a84f/zgfazz-21-9-703-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/bbf67fd3e699/zgfazz-21-9-703-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca20/6136995/aa4fbd89ce82/zgfazz-21-9-703-3.jpg

相似文献

1
[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].[间变性淋巴瘤激酶在非小细胞肺癌中的现状]
Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):703-711. doi: 10.3779/j.issn.1009-3419.2018.09.10.
2
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
3
ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.ALK 融合基因阳性肺癌及 3 例 ALK 激酶活性抑制剂治疗病例。
Lung Cancer. 2012 Jan;75(1):66-72. doi: 10.1016/j.lungcan.2011.05.027. Epub 2011 Jul 14.
4
Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌治疗中的作用
Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836.
5
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.针对 ALK 阳性非小细胞肺癌的精准医学：超越克唑替尼。
Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4.
6
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.P-糖蛋白介导间变性淋巴瘤激酶重排非小细胞肺癌对色瑞替尼的耐药性。
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
7
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.间变性淋巴瘤激酶阳性非小细胞肺癌的诊断与治疗
Hematol Oncol Clin North Am. 2017 Feb;31(1):101-111. doi: 10.1016/j.hoc.2016.08.012.
8
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.用于非小细胞肺癌的I期和II期临床试验中的间变性淋巴瘤激酶抑制剂
Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18.
9
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.ALK重排的晚期非小细胞肺癌（NSCLC）对克唑替尼的耐药性：机制、治疗策略及新的靶向治疗方法
Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134.
10
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.肺癌中间变性淋巴瘤激酶的治疗靶点：精准癌症医学的范例
Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791.

引用本文的文献

1
Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement.ALK抑制剂联合立体定向体部放射治疗对携带EML4-ALK重排的肺鳞癌患者的疗效及耐药性分析
Onco Targets Ther. 2021 Dec 3;14:5385-5389. doi: 10.2147/OTT.S335736. eCollection 2021.
2
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].《中国非小细胞肺癌二代测序诊断专家共识（2020年版）》
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):741-761. doi: 10.3779/j.issn.1009-3419.2020.101.45.
3

本文引用的文献

1
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.恩沙替尼（X-396）治疗间变性淋巴瘤激酶阳性非小细胞肺癌：一项多中心、I/II 期首次人体研究结果。
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.
2
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.色瑞替尼对比化疗用于既往接受过化疗和克唑替尼治疗的ALK重排非小细胞肺癌患者的3期研究（ASCEND-5）：日本亚组
Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.
3
[Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer].
色瑞替尼450毫克随餐服用在中国ALK阳性非小细胞肺癌患者中的安全性及初步疗效
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):655-661. doi: 10.3779/j.issn.1009-3419.2020.102.33.
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
EML4-ALK 变异对 ALK 阳性肺癌耐药机制和临床结局的影响。
J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.
4
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.NGS 和 RT-PCR 方法在欧洲 NSCLC 患者 ALK 重排检测中的评估：来自欧洲胸部肿瘤平台 Lungscape 项目的结果。
J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.
5
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
6
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients.EML4-ALK 变体：生物学和分子特性及其对患者的影响
Cancers (Basel). 2017 Sep 5;9(9):118. doi: 10.3390/cancers9090118.
7
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.间变性淋巴瘤激酶（ALK）在非小细胞肺癌中的现状：新兴的治疗范例和未来方向。
Target Oncol. 2017 Dec;12(6):709-718. doi: 10.1007/s11523-017-0526-1.
8
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).ASCEND-8：一项随机、1 期研究，评估塞瑞替尼 450mg 或 600mg 随低脂餐服用与 750mg 空腹服用在间变性淋巴瘤激酶（ALK）重排转移性非小细胞肺癌（NSCLC）患者中的疗效。
J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.
9
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.克唑替尼与化疗用于治疗 ALK 阳性晚期非小细胞肺癌亚洲患者的疗效比较。
Cancer Res Treat. 2018 Jul;50(3):691-700. doi: 10.4143/crt.2017.280. Epub 2017 Jul 6.
10
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.阿来替尼治疗 ALK 阳性非小细胞肺癌的关键性 II 期研究（NP28673 和 NP28761）的汇总全身疗效和安全性数据。
J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.